Teva

Gilead claims FDA okay for Descovy as second PrEP option

An authorised generic made by Teva is due to launch next year, with a more general launch expected after the patent expiry in 2021.

Johnson & Johnson agrees $20.4m settlement in Ohio over opioid crisis

It also settled with two other opioid drugmakers, including a $270m deal with Purdue Pharma and an $85m deal with Teva Pharmaceuticals.

NICE delivers final ‘no’ for Novartis’ migraine treatment Aimovig

Since being approved by the European Commission in  2018, Novartis has seen rivals emerge from Eli Lilly (Emgality) and Teva (Ajovy) introduced to the market.

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Eptinezumab is one of the new migraine prevention drugs in the CGRP inhibitor class, but unlike already-marketed rivals from Amgen/Novartis, Eli Lilly and Teva, it is delivered intravenously rather ... Alder’s drug is given every three months, whereas

Mallinckrodt offloads CDMO for $250m

Both Teva Pharmaceuticals and Purdue Pharma paid $85m and $270m respectively in out of court settlements.

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]